|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009429,
umls-concept:C0022341,
umls-concept:C0030705,
umls-concept:C0035525,
umls-concept:C0205147,
umls-concept:C0205466,
umls-concept:C0220847,
umls-concept:C0439230,
umls-concept:C0444669,
umls-concept:C0525038,
umls-concept:C0556895,
umls-concept:C0871261,
umls-concept:C0982327,
umls-concept:C1533728,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1708943,
umls-concept:C2603343,
umls-concept:C2698872,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-1-22
|
|
pubmed:abstractText |
Substitution of amino acid (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of efficacy of 48-week peginterferon (PEG-IFN) plus ribavirin (RBV) therapy. Here, we determined the efficacy of 72-week PEG-IFN/RBV and the predictive factors to such therapy in a case-control study matched for sex, age, and periods from the start of treatment to initial point of HCV RNA-negative. We compared the treatment efficacy of 72-week regimen in 65 patients with that of 48-week in 130 patients, who were infected with HCV genotype 1b and treated with PEG-IFN/RBV. They consisted mainly of late virological responders (LVR) (HCV RNA-positive at 12 weeks and negative at 24 weeks after start of treatment). Sustained virological response (SVR) was achieved by 61.5% and 32.3% of patients of the 72- and 48-week groups, respectively, while non-virological response was noted in 9.2% and 29.2% of the respective groups. Multivariate analysis identified substitution of aa 70 and 91 (Arg70 and/or Leu91) and duration of treatment (72-week) as independent parameters that significantly influenced SVR. For Arg70 and/or Leu91 of core region, SVR rate was significantly higher in 72- (68.0%) than 48-week group (37.8%). For wild-type of ISDR, SVR rate was significantly higher in 72- (61.2%) than in 48-week group (29.3%). We conclude that 72-week PEG-IFN/RBV improves SVR rate for LVR, especially those with Arg70 and/or Leu91 of core region or wild-type of ISDR. Substitution of aa 70 and 91 is also a useful pretreatment predictor of response to 72-week PEG-IFN/RBV.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1096-9071
|
|
pubmed:author |
pubmed-author:AkutaNorioN,
pubmed-author:AraseYasujiY,
pubmed-author:HirakawaMiharuM,
pubmed-author:HosakaTetsuyaT,
pubmed-author:IkedaKenjiK,
pubmed-author:KawamuraYusukeY,
pubmed-author:KobayashiMarikoM,
pubmed-author:KobayashiMasahiroM,
pubmed-author:KumadaHiromitsuH,
pubmed-author:SaitohSatoshiS,
pubmed-author:SezakiHitomiH,
pubmed-author:SuzukiFumitakaF,
pubmed-author:SuzukiYoshiyukiY,
pubmed-author:YatsujiHiromiH
|
|
pubmed:copyrightInfo |
Copyright 2009 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
81
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
452-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19152407-Adult,
pubmed-meshheading:19152407-Aged,
pubmed-meshheading:19152407-Amino Acid Substitution,
pubmed-meshheading:19152407-Antiviral Agents,
pubmed-meshheading:19152407-Case-Control Studies,
pubmed-meshheading:19152407-Drug Therapy, Combination,
pubmed-meshheading:19152407-Female,
pubmed-meshheading:19152407-Hepacivirus,
pubmed-meshheading:19152407-Hepatitis C, Chronic,
pubmed-meshheading:19152407-Humans,
pubmed-meshheading:19152407-Interferon-alpha,
pubmed-meshheading:19152407-Japan,
pubmed-meshheading:19152407-Male,
pubmed-meshheading:19152407-Middle Aged,
pubmed-meshheading:19152407-Mutation, Missense,
pubmed-meshheading:19152407-Polyethylene Glycols,
pubmed-meshheading:19152407-RNA, Viral,
pubmed-meshheading:19152407-Recombinant Proteins,
pubmed-meshheading:19152407-Ribavirin,
pubmed-meshheading:19152407-Sequence Analysis, DNA,
pubmed-meshheading:19152407-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
|
|
pubmed:affiliation |
Department of Hepatology, Toranomon Hospital, Tokyo, Japan. akuta-gi@umin.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
